172 related articles for article (PubMed ID: 36332698)
1. Marginal association of fasting blood glucose with the risk of cystic fibrosis-related diabetes.
Potter KJ; Bonhoure A; Boudreau V; Tremblay F; Lavoie A; Carricart M; Senior PA; Rabasa-Lhoret R
Ann Endocrinol (Paris); 2023 Apr; 84(2):265-271. PubMed ID: 36332698
[TBL] [Abstract][Full Text] [Related]
2. Predictors for future cystic fibrosis-related diabetes by oral glucose tolerance test.
Schmid K; Fink K; Holl RW; Hebestreit H; Ballmann M
J Cyst Fibros; 2014 Jan; 13(1):80-5. PubMed ID: 23809507
[TBL] [Abstract][Full Text] [Related]
3. The course of glucose intolerance in children with cystic fibrosis: a retrospective study - preliminary report.
Piechowiak K; Trippenbach-Dulska H; Walicka-Serzysko K
Dev Period Med; 2015; 19(1):80-91. PubMed ID: 26003073
[TBL] [Abstract][Full Text] [Related]
4. Impaired fasting glucose in cystic fibrosis.
Frohnert BI; Ode KL; Moran A; Nathan BM; Laguna T; Holme B; Thomas W
Diabetes Care; 2010 Dec; 33(12):2660-4. PubMed ID: 21115768
[TBL] [Abstract][Full Text] [Related]
5. Oral glucose tolerance test and continuous glucose monitoring to assess diabetes development in cystic fibrosis patients.
Clemente León M; Bilbao Gassó L; Moreno-Galdó A; Campos Martorrell A; Gartner Tizzano S; Yeste Fernández D; Carrascosa Lezcano A
Endocrinol Diabetes Nutr (Engl Ed); 2018 Jan; 65(1):45-51. PubMed ID: 29137964
[TBL] [Abstract][Full Text] [Related]
6. Natural history of glucose intolerance in patients with cystic fibrosis: ten-year prospective observation program.
Sterescu AE; Rhodes B; Jackson R; Dupuis A; Hanna A; Wilson DC; Tullis E; Pencharz PB
J Pediatr; 2010 Apr; 156(4):613-7. PubMed ID: 19962154
[TBL] [Abstract][Full Text] [Related]
7. Use of hemoglobin A1c to identify dysglycemia in cystic fibrosis.
Darukhanavala A; Van Dessel F; Ho J; Hansen M; Kremer T; Alfego D
PLoS One; 2021; 16(4):e0250036. PubMed ID: 33882078
[TBL] [Abstract][Full Text] [Related]
8. Combined Indeterminate and Impaired Glucose Tolerance Is a Novel Group at High Risk of Cystic Fibrosis-Related Diabetes.
Potter KJ; Reynaud Q; Boudreau V; Racine F; Tremblay F; Lavoie A; Carricart M; Mailhot G; Durieu I; Senior PA; Rabasa-Lhoret R
J Clin Endocrinol Metab; 2021 Sep; 106(10):e3901-e3910. PubMed ID: 34132785
[TBL] [Abstract][Full Text] [Related]
9. [Value of continuous glucose monitoring in screening for diabetes in cystic fibrosis].
Khammar A; Stremler N; Dubus JC; Gross G; Sarles J; Reynaud R
Arch Pediatr; 2009 Dec; 16(12):1540-6. PubMed ID: 19854630
[TBL] [Abstract][Full Text] [Related]
10. Cystic fibrosis related diabetes mellitus - diagnostic and management challenges.
Lek N; Acerini CL
Curr Diabetes Rev; 2010 Jan; 6(1):9-16. PubMed ID: 20034372
[TBL] [Abstract][Full Text] [Related]
11. Drug treatments for managing cystic fibrosis-related diabetes.
Onady GM; Stolfi A
Cochrane Database Syst Rev; 2020 Oct; 10(10):CD004730. PubMed ID: 33075159
[TBL] [Abstract][Full Text] [Related]
12. Clinical importance of cystic fibrosis-related diabetes.
Brennan AL; Geddes DM; Gyi KM; Baker EH
J Cyst Fibros; 2004 Dec; 3(4):209-22. PubMed ID: 15698938
[TBL] [Abstract][Full Text] [Related]
13. Continuous glucose monitoring and advanced glycation endproducts for prediction of clinical outcomes and development of cystic fibrosis-related diabetes in adults with CF.
Scully KJ; Brenner L; Martin K; Ruazol M; Sawicki GS; Uluer A; Neuringer I; Yonker LM; Sicilian L; Putman MS
Front Endocrinol (Lausanne); 2024; 15():1293709. PubMed ID: 38379863
[TBL] [Abstract][Full Text] [Related]
14. Diabetes in cystic fibrosis: multicenter screening results based on current guidelines.
Scheuing N; Holl RW; Dockter G; Fink K; Junge S; Naehrlich L; Smaczny C; Staab D; Thalhammer G; van Koningsbruggen-Rietschel S; Ballmann M
PLoS One; 2013; 8(12):e81545. PubMed ID: 24324701
[TBL] [Abstract][Full Text] [Related]
15. Peak glucose during an oral glucose tolerance test is associated with future diabetes risk in adults with cystic fibrosis.
Bonhoure A; Potter KJ; Colomba J; Boudreau V; Bergeron C; Desjardins K; Carricart M; Tremblay F; Lavoie A; Rabasa-Lhoret R
Diabetologia; 2021 Jun; 64(6):1332-1341. PubMed ID: 33693987
[TBL] [Abstract][Full Text] [Related]
16. Insulinogenic index and early phase insulin secretion predict increased risk of worsening glucose tolerance and of cystic fibrosis-related diabetes.
Potter KJ; Boudreau V; Bonhoure A; Tremblay F; Lavoie A; Carricart M; Senior PA; Rabasa-Lhoret R
J Cyst Fibros; 2023 Jan; 22(1):50-58. PubMed ID: 36028423
[TBL] [Abstract][Full Text] [Related]
17. Glycated Hemoglobin as a First-line Screening Test for Cystic Fibrosis‒Related Diabetes and Impaired Glucose Tolerance in Children With Cystic Fibrosis: A Validation Study.
Racine F; Shohoudi A; Boudreau V; Nguyen CQT; Denis MH; Desjardins K; Reynaud Q; Rabasa-Lhoret R; Mailhot G
Can J Diabetes; 2021 Dec; 45(8):768-774. PubMed ID: 33926819
[TBL] [Abstract][Full Text] [Related]
18. A glycosylated hemoglobin A1c above 6% (42 mmol/mol) is associated with a high risk of developing Cystic Fibrosis-Related Diabetes and a lower probability of weight gain in both adults and children with Cystic Fibrosis.
Potter KJ; Racine F; Bonhoure A; Boudreau V; Bélanger N; Coriati A; Shohoudi A; Lavoie A; Senior PA; Mailhot G; Rabasa-Lhoret R
Diabetes Metab; 2023 Jul; 49(4):101455. PubMed ID: 37271306
[TBL] [Abstract][Full Text] [Related]
19. Sensitivity and specificity of different methods for cystic fibrosis-related diabetes screening: is the oral glucose tolerance test still the standard?
Mainguy C; Bellon G; Delaup V; Ginoux T; Kassai-Koupai B; Mazur S; Rabilloud M; Remontet L; Reix P
J Pediatr Endocrinol Metab; 2017 Jan; 30(1):27-35. PubMed ID: 27977404
[TBL] [Abstract][Full Text] [Related]
20. Report of the Committee on the classification and diagnostic criteria of diabetes mellitus.
Kuzuya T; Nakagawa S; Satoh J; Kanazawa Y; Iwamoto Y; Kobayashi M; Nanjo K; Sasaki A; Seino Y; Ito C; Shima K; Nonaka K; Kadowaki T;
Diabetes Res Clin Pract; 2002 Jan; 55(1):65-85. PubMed ID: 11755481
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
